Immunotherapy in pancreatic cancer treatment: A new frontier

Komal Thind, Leslie J. Padrnos, Ramesk K Ramanathan, Mitesh J Borad

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Pancreatic cancer is a highly aggressive and lethal cancer characterized by high invasiveness, local and extensive dissemination at time of diagnosis and resistance to treatment. Few therapies have shown efficacy in the past and even standard of care therapies yield only modest improvements in the mortality of patients with advanced or metastatic disease. Efforts have been undertaken to study the pancreatic tumor microenvironment and have established its complex and immunosuppressive nature which could explain the high resistance to chemotherapy. Novel therapies targeting the tumor microenvironment with an aim to decrease this resistance, improve immune tolerance and increase the efficacy of the current treatment have shown some promising preliminary results in preclinical and clinical trials. We review the current advances in the field of immunotherapy and their effectiveness as a potential treatment strategy in the pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)168-194
Number of pages27
JournalTherapeutic Advances in Gastroenterology
Volume10
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Pancreatic Neoplasms
Immunotherapy
Tumor Microenvironment
Therapeutics
Immune Tolerance
Standard of Care
Immunosuppressive Agents
Clinical Trials
Drug Therapy
Mortality
Neoplasms

Keywords

  • adoptive cellular immunotherapy
  • cancer vaccines
  • immunotherapy
  • pancreatic cancer

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Immunotherapy in pancreatic cancer treatment : A new frontier. / Thind, Komal; Padrnos, Leslie J.; Ramanathan, Ramesk K; Borad, Mitesh J.

In: Therapeutic Advances in Gastroenterology, Vol. 10, No. 1, 01.01.2017, p. 168-194.

Research output: Contribution to journalReview article

@article{caff0bbbe72d4c6e82f91137fdbec1bc,
title = "Immunotherapy in pancreatic cancer treatment: A new frontier",
abstract = "Pancreatic cancer is a highly aggressive and lethal cancer characterized by high invasiveness, local and extensive dissemination at time of diagnosis and resistance to treatment. Few therapies have shown efficacy in the past and even standard of care therapies yield only modest improvements in the mortality of patients with advanced or metastatic disease. Efforts have been undertaken to study the pancreatic tumor microenvironment and have established its complex and immunosuppressive nature which could explain the high resistance to chemotherapy. Novel therapies targeting the tumor microenvironment with an aim to decrease this resistance, improve immune tolerance and increase the efficacy of the current treatment have shown some promising preliminary results in preclinical and clinical trials. We review the current advances in the field of immunotherapy and their effectiveness as a potential treatment strategy in the pancreatic cancer.",
keywords = "adoptive cellular immunotherapy, cancer vaccines, immunotherapy, pancreatic cancer",
author = "Komal Thind and Padrnos, {Leslie J.} and Ramanathan, {Ramesk K} and Borad, {Mitesh J}",
year = "2017",
month = "1",
day = "1",
doi = "10.1177/1756283X16667909",
language = "English (US)",
volume = "10",
pages = "168--194",
journal = "Therapeutic Advances in Gastroenterology",
issn = "1756-283X",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Immunotherapy in pancreatic cancer treatment

T2 - A new frontier

AU - Thind, Komal

AU - Padrnos, Leslie J.

AU - Ramanathan, Ramesk K

AU - Borad, Mitesh J

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Pancreatic cancer is a highly aggressive and lethal cancer characterized by high invasiveness, local and extensive dissemination at time of diagnosis and resistance to treatment. Few therapies have shown efficacy in the past and even standard of care therapies yield only modest improvements in the mortality of patients with advanced or metastatic disease. Efforts have been undertaken to study the pancreatic tumor microenvironment and have established its complex and immunosuppressive nature which could explain the high resistance to chemotherapy. Novel therapies targeting the tumor microenvironment with an aim to decrease this resistance, improve immune tolerance and increase the efficacy of the current treatment have shown some promising preliminary results in preclinical and clinical trials. We review the current advances in the field of immunotherapy and their effectiveness as a potential treatment strategy in the pancreatic cancer.

AB - Pancreatic cancer is a highly aggressive and lethal cancer characterized by high invasiveness, local and extensive dissemination at time of diagnosis and resistance to treatment. Few therapies have shown efficacy in the past and even standard of care therapies yield only modest improvements in the mortality of patients with advanced or metastatic disease. Efforts have been undertaken to study the pancreatic tumor microenvironment and have established its complex and immunosuppressive nature which could explain the high resistance to chemotherapy. Novel therapies targeting the tumor microenvironment with an aim to decrease this resistance, improve immune tolerance and increase the efficacy of the current treatment have shown some promising preliminary results in preclinical and clinical trials. We review the current advances in the field of immunotherapy and their effectiveness as a potential treatment strategy in the pancreatic cancer.

KW - adoptive cellular immunotherapy

KW - cancer vaccines

KW - immunotherapy

KW - pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=85006339723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006339723&partnerID=8YFLogxK

U2 - 10.1177/1756283X16667909

DO - 10.1177/1756283X16667909

M3 - Review article

AN - SCOPUS:85006339723

VL - 10

SP - 168

EP - 194

JO - Therapeutic Advances in Gastroenterology

JF - Therapeutic Advances in Gastroenterology

SN - 1756-283X

IS - 1

ER -